Jean‐Philippe Lanoix

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites et al. · The Lancet Infectious Diseases · 2021 · 338 citations · Full text

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis

Jean‐Philippe Lanoix, Anne J. Lenaerts, Eric L. Nuermberger · Disease Models & Mechanisms · 2015 · 134 citations · Full text

Incubation Period, Tuberculosis Prevention, Immunology +16

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy et al. · Clinical Microbiology and Infection · 2021 · 102 citations · Full text

Clinical Infectious Disease, Open-label Randomized, Antiviral Drug Development +6

Characteristics and outcomes of<scp>COVID</scp>‐19 in hospitalized patients with and without diabetes

Abdallah Al‐Salameh, Jean‐Philippe Lanoix, Youssef Bennis et al. · Diabetes/Metabolism Research and Reviews · 2020 · 86 citations · Full text

Mutations in <i>fbiD</i> ( <i>Rv2983</i> ) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis

Dalin Rifat, Si-Yang Li, Thomas R. Ioerger et al. · Antimicrobial Agents and Chemotherapy · 2020 · 84 citations · Full text